Therapeutic response to rituximab in seropositive neuromyelitis optica: Experience from a tertiary care center in South India

OBJECTIVES: Neuromyelitis optica (NMO) is a severe central nervous system demyelinating disease caused by autoantibodies to anti-aquaporin-4 immunoglobulin-G (AQP4-IgG). Rituximab, a monoclonal antibody targeting CD20 cells, is effective in neuromyelitis optica spectrum disorder (NMOSD) in several o...

Descripción completa

Detalles Bibliográficos
Autores principales: James, Joe, Gafoor, V. Abdul, Jose, James, Smita, B., Balaram, Neetha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Scientific Scholar 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10174152/
https://www.ncbi.nlm.nih.gov/pubmed/37181182
http://dx.doi.org/10.25259/JNRP_59_2022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10174152/
https://www.ncbi.nlm.nih.gov/pubmed/37181182
http://dx.doi.org/10.25259/JNRP_59_2022

Ejemplares similares